The challenge of small lung nodules identified in CT screening: Can biomarkers assist diagnosis?

Biomarkers in Medicine

Volumn 10, Issue 2, 2016, Pages 137-143

  Veronesi, Giulia ^a   Bianchi, Fabrizio ^b   Infante, Maurizio ^a   Alloisio, Marco ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Biomarkers; early diagnosis; low dose computed tomography; lung cancer; screening

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C4D; MICRORNA; MICRORNA 126; MICRORNA 155; MICRORNA 15B; MICRORNA 197; MICRORNA 21; MICRORNA 210; MICRORNA 223; MICRORNA 25; MICRORNA 27B; MICRORNA 486 5P; PENTRAXIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADENOCARCINOMA; BLOOD; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; EARLYCDT LUNG TEST; HOST; HUMAN; INNATE IMMUNITY; LOW DOSE COMPUTED TOMOGRAPHY; LUNG CANCER; LUNG NODULE; MIR TEST; MSC TEST; NON SMALL CELL LUNG CANCER; PROTEIN BLOOD LEVEL; REVIEW; SMALL LUNG NODULE; SPUTUM; SQUAMOUS CELL CARCINOMA; ASYMPTOMATIC DISEASE; DIAGNOSTIC IMAGING; EPITHELIUM CELL; LUNG; LUNG NEOPLASMS; MASS SCREENING; PATHOLOGY; SENSITIVITY AND SPECIFICITY; X-RAY COMPUTED TOMOGRAPHY;

ASYMPTOMATIC DISEASES; BIOMARKERS, TUMOR; EPITHELIAL CELLS; HUMANS; IMMUNITY, INNATE; LUNG; LUNG NEOPLASMS; MASS SCREENING; MICRORNAS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84961326061     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.15.122     Document Type: Review

References (40)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. National Cancer Institute. SEER Cancer Statistics Review, 1975-2006. http://seer.cancer.gov/csr/1975-2006 3
3. Diederich S, Thomas M, Semik M et al. Screening for early lung cancer with low-dose spiral computed tomography: results of annual follow-up examinations in asymptomatic smokers. Eur. Radiol. 14(4), 691 (2004).
4. Henschke CI, McCauley DI, Yankelevitz DF et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 354(9173), 99-105 (1999).
5. Sone S, Li F, Yang ZG, Takashima S et al. Characteristics of small lung cancers invisible on conventional chest radiography and detected by population based screening using spiral CT. Br. J. Radiol. 73(866), 137-145 (2000).
6. Veronesi G, Maisonneuve P, Spaggiari L et al. Diagnostic performance of LD-CT screening for lung cancer over five years. J. Thorac. Oncol. 9(7), 935-939 (2014).
7. Veronesi G, Maisonneuve P, Spaggiari L et al. Longterm outcomes of a pilot CT screening for lung cancer. Ecancermedicalscience 4, 186 (2010).
8. van Klaveren RJ, Oudkerk M, Prokop M et al. Management of lung nodules detected by volume CT scanning. N. Engl. J. Med. 361(23), 2221-2229 (2009).
9. Veronesi G, Bellomi M, Veronesi U et al. Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. Ann. Thorac. Surg. 84, 959-965 (2007).
10. Veronesi G, Travaini LL, Maisonneuve P et al. Positron emission tomography in the diagnostic work-up of screeningdetected lung nodules. Eur. Respir. J. 45(2), 501-510 (2015).
11. Ashraf H, Dirksen A, Loft A et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax 66, 315-319 (2011).
12. National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 365, 395-409 (2011).
13. National Lung Screening Trial Research Team; Church TR, Black WC, Aberle DR et al. Results of initial low-dose computed tomographic screening for lung cancer. N. Engl. J. Med. 368(21), 1980-1991 (2013).
14. Yip R, Henschke CI, Yankelevitz DF, Boffetta P, Smith JP. International Early Lung Cancer Investigators. The impact of the regimen of screening on lung cancer cure: a comparison of I-ELCAP and NLST. Eur. J. Cancer Prev. 24(3), 201-208 (2015).
15. Moyer VA. U.S. Preventive Services Task Force Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 160(5), 330-338 (2014).
16. Smith RA, Manassaram-Baptiste D, Brooks D et al. Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J. Clin. 64(1), 30-51 (2014).
17. Infante M, Cavuto S, Lutman FR et al. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am. J. Respir. Crit. Care Med. 191(10), 1166-1175 (2015).
18. Maisonneuve P, Bagnardi V, Bellomi M et al. Lung cancer risk prediction to select smokers for screening CT-a model based on the Italian COSMOS trial. Cancer Prev. Res. (Phila.) 4(11), 1778-1789 (2011).
19. Kratz JR, He J, Van Den Eeden SK et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379, 823-832 (2012).
20. Sozzi G, Boeri M. Potential biomarkers for lung cancer screening. Transl. Lung Cancer Res. 3(3), 139-148 (2014).
21. Pepe MS, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93(14), 1054-1061 (2001).
22. Ajona D, Pajares MJ, Corrales L et al. Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst. 105(18), 1385-1393 (2013).
23. Infante M, Allavena P, Garlanda C et al. Prognostic and diagnostic potential of local and circulating levels of pentraxin 3 in lung cancer patients. Int. J. Cancer doi:10.1002/ijc.29822 (2015) (Epub ahead of print).
24. Chapman CJ, Healey GF, Murray A et al. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol. 33, 1319-26 (2012).
25. Lam S, Boyle P, Healey GF et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev. Res. (Phila.) 4, 1126-1134 (2011).
26. Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JF. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer 83, 51-55 (2014).
27. University of Nottingham: NHS Scotland evaluates new blood test for lung cancer. www.nottingham.ac.uk
28. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J. Thorac. Oncol. 1(6), 513-519 (2006).
29. Mehan MR, Williams SA, Siegfried JM et al. Validation of a blood protein signature for non-small cell lung cancer. Clin. Proteomics 11(1), 32 (2014).
30. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 18(10), 997-1006 (2008).
31. Shen J, Todd NW, Zhang H et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 91, 579-587 (2011).
32. Zheng D, Haddadin S, Wang Y et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int. J. Clin. Exp. Pathol. 4, 575-586 (2011).
33. Hennessey PT, Sanford T, Choudhary A et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS ONE 7(2), e32307 (2012).
34. Bianchi F, Nicassio F, Marzi M et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol. Med. 3, 495-503 (2011).
35. Boeri M, Verri C, Conte D et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc. Natl Acad. Sci. USA 108, 3713-3718 (2011).
36. Montani F, Marzi MJ, Dezi F et al. miR-Test: a blood test for lung cancer early detection. J. Natl Cancer Inst. 107(6), djv063 (2015).
37. Sozzi G, Boeri M, Rossi M et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J. Clin. Oncol. 32(8), 768-773 (2014).
38. Pastorino U, Rossi M, Rosato V et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur. J. Cancer Prev. 21, 308-315 (2012).
39. Wilbur DC, Meyer MG, Presley C et al. Automated 3-dimensional morphologic analysis of sputum specimens for lung cancer detection: performance characteristics support use in lung cancer screening. Cancer Cytopathol. 123(9), 548-545 (2015).
40. Ilie M, Hofman V, Long-Mira E, Selva E et al. "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS ONE 9(10), e111597 (2014).